CureDuchenne Joins AMP BGTC
CureDuchenne joins forces with NIH, FDA, and private organizations to increase effective gene therapies for rare diseases
CureDuchenne is delighted to be a partner in the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium and has great expectations for future gene therapy research and treatments emerging from this effort.
The goals of this initiative have the potential to transform the field of gene therapy and align with both the vision and mission of CureDuchenne. We are committed to making gene therapy more accessible to a wider array of diseases and larger number of individuals. The learnings gained from this initiative will not only inform best practices, but also lower the barriers for future gene therapy programs.
To learn more about this development, please read the press release here: https://fnih.org/news/press-releases/fnih-announces-transformative-partnership-streamline-development-treatments